Literature DB >> 8811309

Immunologic dysfunction in cancer.

D Y Kavanaugh1, D P Carbone.   

Abstract

The interactions between the tumor and its host are complex, and many aspects of the immune system appear to be adversely affected directly or indirectly by the presence of the tumor. Virtually all of the processes involved in immune induction and action have been implicated in the observed deficient response in tumor-bearing patients. Improved understanding and molecular analysis of the mechanisms underlying the escape of tumors from immune surveillance may lead to the development of novel strategies for the prevention of T-cell immunosuppression in cancer patients, the development of novel immunotherapeutic strategies, and potentially prevention of tumor progression or development.

Entities:  

Mesh:

Year:  1996        PMID: 8811309     DOI: 10.1016/s0889-8588(05)70376-2

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  10 in total

Review 1.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Use of reporter genes for optical measurements of neoplastic disease in vivo.

Authors:  C H Contag; D Jenkins; P R Contag; R S Negrin
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 3.  VEGF as a mediator of tumor-associated immunodeficiency.

Authors:  J E Ohm; D P Carbone
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

4.  Expression of invasion markers CD44v6/v3, NM23 and MMP2 in laryngeal and hypopharyngeal carcinoma.

Authors:  G Répássy; C Forster-Horváth; A Juhász; R Adány; A Tamássy; J Tímár
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

5.  Diminished expression of transcription factors nuclear factor kappaB and CCAAT/enhancer binding protein underlies a novel tumor evasion mechanism affecting macrophages of mammary tumor-bearing mice.

Authors:  Marta Torroella-Kouri; Xiaojing Ma; Giselle Perry; Milena Ivanova; Pedro J Cejas; Jennifer L Owen; Vijaya Iragavarapu-Charyulu; Diana M Lopez
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

6.  Bone marrow-derived dendritic cells under influence of experimental breast cancer and physical activity.

Authors:  Douglas R Abdalla; Bruno B M Gomes; Eddie F C Murta; Márcia A Michelin
Journal:  Oncol Lett       Date:  2017-01-11       Impact factor: 2.967

Review 7.  Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.

Authors:  Swethajit Biswas; Tim Eisen
Journal:  Nat Rev Clin Oncol       Date:  2009-06-23       Impact factor: 66.675

8.  Stratified Threshold Values of QuantiFERON Assay for Diagnosing Tuberculosis Infection in Immunocompromised Populations.

Authors:  Haruyuki Ariga; Hideaki Nagai; Atsuyuki Kurashima; Yoshihiko Hoshino; Syunsuke Shoji; Yutsuki Nakajima
Journal:  Tuberc Res Treat       Date:  2011-06-27

9.  Harnessing dendritic cells for tumor antigen presentation.

Authors:  Stefan Nierkens; Edith M Janssen
Journal:  Cancers (Basel)       Date:  2011-04-26       Impact factor: 6.639

10.  Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.

Authors:  Hyo Min Ahn; JinWoo Hong; Chae-Ok Yun
Journal:  Oncotarget       Date:  2016-12-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.